Compare NFE & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NFE | CTSO |
|---|---|---|
| Founded | 2014 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.6M | 23.9M |
| IPO Year | 2018 | 2008 |
| Metric | NFE | CTSO |
|---|---|---|
| Price | $3.45 | $5.25 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $12.25 |
| AVG Volume (30 Days) | ★ 413.9K | 55.7K |
| Earning Date | 11-20-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.79 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,504,037,000.00 | $22,503,908.00 |
| Revenue This Year | $108.26 | $4.91 |
| Revenue Next Year | $3.52 | $13.58 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 48.53 |
| 52 Week Low | $0.23 | $0.30 |
| 52 Week High | $16.90 | $7.44 |
| Indicator | NFE | CTSO |
|---|---|---|
| Relative Strength Index (RSI) | 40.06 | 63.40 |
| Support Level | $0.40 | $2.88 |
| Resistance Level | $7.13 | $7.44 |
| Average True Range (ATR) | 0.41 | 0.64 |
| MACD | -0.25 | 0.18 |
| Stochastic Oscillator | 3.42 | 63.59 |
New Fortress Energy Inc is an integrated gas-to-power company. It owns and operates natural gas and liquefied natural gas (LNG) infrastructure, and an integrated fleet of ships and logistics assets to deliver turnkey energy solutions to markets globally. The company's reportable segments are: Terminals and Infrastructure, and Ships. Maximum revenue is generated from the Terminals and Infrastructure segment, which includes vertically integrated gas-to-power solutions, spanning the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, facilities, and conversion or development of natural gas-fired power generation. Vessels that are utilized in the company's terminal, logistics, or sub-charter operations are included in this segment.
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.